J&J eyes $100B revenue with AI imaging, surgical robots

Key Takeaways

• J&J expects to surpass $100 billion in annual revenue for the first time in its 140-year history
• Cartosound Sonata brings AI-based imaging to cardiac electrophysiology for more accurate heart mapping
• The Ottava robotic surgical system is progressing toward FDA authorization as J&J's flagship MedTech bet

Johnson & Johnson expects to hit $100 billion in annual revenue this year, a first in its 140-year history. The pharma and MedTech giant is betting on AI-powered cardiac imaging, a bladder cancer drug delivery system, and a table-integrated surgical robot to drive the milestone.

CEO Joaquin Duato laid out the case during the company's Q2 2026 earnings call on Wednesday. Second-quarter operational sales rose 5.6% to $25.3 billion, with the Innovative Medicine unit up 6.8% to $16.4 billion and MedTech climbing 3.6% to $8.9 billion.

What is Cartosound Sonata?

J&J launched Cartosound Sonata in April, bringing AI-based imaging and mapping to electrophysiology. The system uses machine learning to build three-dimensional models of heart chambers, helping physicians diagnose and treat arrhythmias with greater precision.

Electrophysiology has historically relied on fluoroscopy and manual catheter positioning. AI-generated maps reduce radiation exposure for patients and shorten procedure times. For J&J, the product strengthens its position in a cardiac ablation market projected to exceed $8 billion by 2028.

Duato called the launch a capability expansion rather than a product replacement. The tool works alongside J&J's existing Biosense Webster catheter portfolio, which already commands significant market share in ablation procedures.

Ottava: the surgical robot J&J calls its biggest MedTech bet

J&J is progressing toward FDA authorization for Ottava, a robotic surgical system that integrates directly into the operating table. Duato described it as "one of the most significant MedTech innovations we will bring to market this decade."

Unlike competitors that require separate robotic carts, Ottava's table-integrated design aims to reduce operating room footprint and setup time. The system targets general surgery, urology, and gynecology procedures.

J&J is late to surgical robotics. Intuitive Surgical's da Vinci platform has dominated for two decades. But J&J believes a differentiated form factor and digital integration can carve out share in a market growing at 25% annually.

Inlexzo gains early sales momentum in bladder cancer

The company also highlighted Inlexzo, a drug-releasing system approved by the FDA in September 2025. The device delivers extended local release of cancer medication directly into the bladder, targeting patients with non-muscle invasive bladder cancer who cannot tolerate or have failed standard therapy.

Duato said J&J is "encouraged by early momentum" in Inlexzo sales, though he did not disclose specific figures. The product represents J&J's push into localized oncology treatments, a category that reduces systemic toxicity compared to intravenous chemotherapy.

Why the $100 billion target matters now

J&J completed its separation from consumer health spinoff Kenvue in 2023. The remaining company focuses entirely on pharmaceuticals and medical devices. Revenue concentration in these higher-margin segments accelerates the path to $100 billion.

The target also signals confidence in the company's pipeline. J&J faces biosimilar competition to several blockbuster drugs in the next five years. MedTech acquisitions and AI-driven products are meant to offset that revenue pressure.

Duato framed the strategy as building "a pipeline that will transform care for patients tomorrow" while delivering strong performance today. For investors, the balance between near-term execution and long-term bets defines whether J&J can sustain growth beyond the $100 billion mark.

What competitors does J&J face in surgical robotics?

Intuitive Surgical remains the dominant player with over 8,000 da Vinci systems installed globally. Medtronic's Hugo system, Stryker's Mako platform for orthopedics, and Asensus Surgical's Senhance system also compete for hospital contracts.

J&J's differentiation strategy centers on table integration and a digital ecosystem that connects pre-operative planning, intraoperative guidance, and post-surgical analytics. The company argues this workflow approach will appeal to hospital administrators focused on efficiency.

Frequently Asked Questions

When will J&J's Ottava surgical robot receive FDA approval?

J&J has not provided a specific date but says it is progressing toward potential FDA authorization. Industry observers expect a decision in late 2026 or 2027.

How does Cartosound Sonata use AI in cardiac procedures?

The system applies machine learning to ultrasound imaging to generate three-dimensional maps of heart chambers, helping physicians visualize arrhythmia sources during ablation procedures.

What is J&J's MedTech revenue breakdown?

In Q2 2026, J&J's MedTech segment generated $8.9 billion in sales, up 3.6% operationally. The segment includes surgical devices, orthopedics, and cardiovascular products.

How does Inlexzo treat bladder cancer?

Inlexzo is an implantable drug-releasing system that delivers cancer medication directly into the bladder over an extended period, targeting patients with non-muscle invasive bladder cancer.

Has J&J ever reached $100 billion in annual revenue before?

No. If J&J hits this target in 2026, it will be the first time in the company's 140-year history.

Source: PYMNTS | / PYMNTS